Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study
J Hoffmann - The American journal of medicine, 1997 - Elsevier
PURPOSE: To compare the therapeutic potential of acarbose, metformin, or placebo as first
line treatment in patients with non-insulin-dependent diabetes mellitus (NIDDM). PATIENTS
AND METHODS: Ninety-six patients with NIDDM (35–70 years of age, body mass index
(BMI)≤ 35 kg/m2, insufficiently treated with diet alone, glycated hemoglobin (HbA1C; 7% to
11%) were randomized into 3 groups and treated for 24 weeks with acarbose, 3× 100
mg/day, or metformin, 2× 850 mg/day, or placebo. Efficacy, based on HbA1C (primary …
line treatment in patients with non-insulin-dependent diabetes mellitus (NIDDM). PATIENTS
AND METHODS: Ninety-six patients with NIDDM (35–70 years of age, body mass index
(BMI)≤ 35 kg/m2, insufficiently treated with diet alone, glycated hemoglobin (HbA1C; 7% to
11%) were randomized into 3 groups and treated for 24 weeks with acarbose, 3× 100
mg/day, or metformin, 2× 850 mg/day, or placebo. Efficacy, based on HbA1C (primary …